SEC
RXRX icon

Seven Eight Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Seven Eight Capital’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-26,001
Closed -$445K – 673
2021
Q4 		$445K Buy
+26,001
New +$489K 0.08% 291

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OMS
Obvious Management Services San Francisco, California $42.4M AUM 54.5% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Seven Eight Capital's RXRX Position: Q1 2022 in Review

Seven Eight Capital sold out of Recursion Pharmaceuticals (RXRX) in Q1 2022, closing a stake of 26,001 shares — an estimated $445K sold.

Seven Eight Capital first reported a position in RXRX in Q4 2021 and held it in 1 quarter. The position peaked at $445K in Q4 2021. 128 funds tracked by Wall St. Rank hold RXRX as of Q1 2022.

  • Seven Eight Capital reported no remaining Recursion Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Seven Eight Capital sold 26,001 Recursion Pharmaceuticals shares in Q1 2022, an estimated $445K.
  • Seven Eight Capital first reported a position in Recursion Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Seven Eight Capital's Recursion Pharmaceuticals position peaked at $445K in Q4 2021.
  • 128 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2022.

Based on Seven Eight Capital's 13F filing for Q1 2022, filed 11 May 2022.